Normalization of hypercalcaemia of primary hyperparathyroidism by treatment with methallenestril, a synthetic oestrogen with low oestrogenicity.
The oestrogenic compound methallenestril has a relatively low oestrogenicity but a marked growth-inhibiting property in experimental studies. Methallenestril was administered in a dose of 6 mg daily to 6 postmenopausal women with hypercalcaemia and primary hyperparathyroidism (HPT) for periods between 5 and 24 weeks. In all the patients, serum calcium was normalized during treatment, presumably due to a reduction of bone resorption since fasting urinary calcium and urinary hydroxyproline excretion were lowered as well. This pilot study indicates that certain oestrogenic compounds with high potencies for growth inhibition but with low oestrogenic properties might be worth further investigation in the medical management of primary HPT.
D000368:Aged; D002118:Calcium / Q000097:blood / Q000652:urine; D004968:Estrogens, Non-Steroidal / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D006934:Hypercalcemia / Q000188:drug therapy*; D006961:Hyperparathyroidism / Q000188:drug therapy*; D008875:Middle Aged; D009281:Naphthalenes / Q000627:therapeutic use*; D010865:Pilot Projects; D013997:Time Factors
D004968:Estrogens, Non-Steroidal; D009281:Naphthalenes; D002118:Calcium; C005194:methallenestril